spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  RNA-targeted 

 HSMN NewsFeed - 26 Jul 2024
ReviR Therapeutics Raises $30 Million Series A Financing to Advance its Proprietary Oral Genetic Medicines for Multiple CNS Disorders
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 29 Dec 2021
Ionis and AstraZeneca close deal to develop and commercialize eplontersen
Biopharmaceuticals
 HSMN NewsFeed - 4 Nov 2021
NeuroBo Pharmaceuticals Appoints Gil Price, M.D. as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jul 2021
Transine Therapeutics Appoints Industry Veteran Jan Thirkettle Ph.D. as CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Apr 2021
Ionis initiates Phase 3 trial of novel antisense medicine to treat leading cause of juvenile-onset ALS
Biopharmaceuticals Neurology
 HSMN NewsFeed - 31 Aug 2020
Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 9 Jan 2020
Ionis Appoints Onaiza Cadoret-Manier As Chief Corporate Development and Commercial Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 5 Jul 2018
New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI(TM) (inotersen) for the Treatment of Hereditary ATTR Amyloidosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 18 Jun 2018
Ionis Pharmaceuticals Appoints Damien McDevitt as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Mar 2018
Ionis and Akcea Partner to Commercialize Inotersen for hATTR
Biopharmaceuticals Licensing
 HSMN NewsFeed - 9 Nov 2017
Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure
Biopharmaceuticals Licensing
 HSMN NewsFeed - 7 Nov 2017
Ionis Announces Management Transitions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jun 2017
SPINRAZA(R) (nusinersen) Approved in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 15 May 2017
Ionis Pharmaceuticals Announces Phase 3 NEURO-TTR Study of Inotersen (IONIS-TTR Rx) Meets Both Primary Endpoints
Biopharmaceuticals
 HSMN NewsFeed - 14 Feb 2017
miRagen Therapeutics Completes Merger with Signal Genetics and Concurrent $40.7 Million Equity Financing
Biopharmaceuticals Mergers & Acquisitions Venture Capital
 HSMN NewsFeed - 26 Dec 2016
SPINRAZA(TM) (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Nov 2016
miRagen Therapeutics and Signal Genetics Sign Merger Agreement
Diagnostics Oncology Mergers & Acquisitions
 HSMN NewsFeed - 19 Jan 2016
Akcea Therapeutics Appoints Louis St. L. O'Dea as Chief Medical Officer
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 5 Jan 2016
Ionis Pharmaceuticals Receives Orphan Drug Designation from the US FDA for IONIS-HTT Rx for the Treatment of Patients with Huntington's Disease
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 6 Jan 2015
Isis Pharmaceuticals Appoints Paula Soteropoulos As President And Chief Executive Officer Of Akcea Therapeutics
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Apr 2013
RXi Pharmaceuticals Appoints H. Paul Dorman and Curtis Lockshin, Ph.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Feb 2008
Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer
Biopharmaceuticals Personnel
Return to NewsFeed  
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!